It's been great to talk to Tom Mackenzie of Bloomberg News about the launch of our protein design model and platform this morning!
August 11, 2025 at 8:58 AM
It's been great to talk to Tom Mackenzie of Bloomberg News about the launch of our protein design model and platform this morning!
Reposted by Simon Kohl
🧬Latent-X is our first frontier model for protein design.
For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.
Explore our best binders here: platform.latentlabs.com
More details on the breakthrough in this🧵
For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.
Explore our best binders here: platform.latentlabs.com
More details on the breakthrough in this🧵
July 25, 2025 at 11:08 AM
🧬Latent-X is our first frontier model for protein design.
For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.
Explore our best binders here: platform.latentlabs.com
More details on the breakthrough in this🧵
For mini-binders, our AI model achieved picomolar binding affinities — the strongest reported vs prior methods in head-to-head lab validation.
Explore our best binders here: platform.latentlabs.com
More details on the breakthrough in this🧵
Introducing Latent-X — our all-atom frontier AI model for protein binder design.
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: platform.latentlabs.com
Blog: latentlabs.com/latent-x/
Technical report: tinyurl.com/latent-X
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: platform.latentlabs.com
Blog: latentlabs.com/latent-x/
Technical report: tinyurl.com/latent-X
July 22, 2025 at 6:21 AM
Introducing Latent-X — our all-atom frontier AI model for protein binder design.
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: platform.latentlabs.com
Blog: latentlabs.com/latent-x/
Technical report: tinyurl.com/latent-X
State-of-the-art lab performance, widely accessible via the Latent Labs Platform.
Free tier: platform.latentlabs.com
Blog: latentlabs.com/latent-x/
Technical report: tinyurl.com/latent-X
Reposted by Simon Kohl
5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design.
Available now on our no-code platform!
Available now on our no-code platform!
July 22, 2025 at 6:02 AM
5 months from funding to shipping our first frontier model. Latent-X achieves state-of-the-art hit rates for macrocycles and mini-binders, with picomolar binding affinities — a breakthrough in de novo protein binder design.
Available now on our no-code platform!
Available now on our no-code platform!
It's been great to discuss our work with @hannahkuchler.bsky.social & @melissahei.bsky.social at the @financialtimes.com!
"Simon Kohl, a scientist, has raised $50M to launch a startup to discover new drugs."
We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social.
www.ft.com/content/9214...
We’re grateful for the incredible response to our mission. Thank you @financialtimes.com, @hannahkuchler.bsky.social & @melissahei.bsky.social.
www.ft.com/content/9214...
Ex-DeepMind scientist launches AI drug discovery venture
Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system
www.ft.com
February 13, 2025 at 1:45 PM
It's been great to discuss our work with @hannahkuchler.bsky.social & @melissahei.bsky.social at the @financialtimes.com!
Latent Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design
February 13, 2025 at 7:00 AM
Latent Labs comes out of stealth today with $50M funding. Our goal? To push the frontiers of generative biology, giving partners instant access to tools capable of accelerating drug design